🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

a Feasibility Study of iHD-SRT for BM

RecruitingNAAges any - anyAllRuijin Hospital
NCT06231186 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Brain metastasis is the most challenging disease in the field of tumor treatment, with a median overall survival of only 1-2 months for untreated patients. Stereotactic radiotherapy (SRT) has the advantages of precise positioning, relatively concentrated dosage, shorter course, and lower toxicity. Several studies could effectively protect cognitive function and achieve better tumor control rate. Currently, it has gradually replaced WBRT as standard local treatment choice for brain metastases. SRT includes Stereotactic Radiosurgery (SRS) and Fractional Stereotactic Radiotherapy (fSRT). With the continuous updating of domestic radiation therapy equipment, the use of high-resolution multi leaf gratings enables the accuracy of fSRT based on linear accelerators to reach 0.5mm or even lower levels, and has gradually become one of the main choices for local treatment of a limited number of pati

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Ability to understand and willingness to participate the research and sign the consent form * ECOG PS 0-2 * The primary or metastatic lesion was confirmed by pathological histology as a malignant tumor * Head MRI diagnosis of brain metastasis with measurable lesions and technically feasible SRT (no more than 15 in number and 20cc in volume) * Estimated survival time ≥ 3 months Exclusion Criteria: * Diffuse brain metastases, or combined with meningeal metastases, or technically difficult to perform SRT * With severe internal medicine complications or absolute contraindications for radiotherapy * other sufficient reasons to be unqualified, such as potential non-compliance with the clinical protocol, etc
💊

What it tests

  • iHD-SRT
📍

Where

1 site
Ruijin Hospital
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy